Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Its new plan for phase 3 trials is advancing.

Is Vaccine Latecomer Inovio Making a Comeback?

PLYMOUTH MEETING, Pa., Sept. 22, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has received authorization from COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), the national health regulatory agency of Mexico, to conduct a clinical trial in that country as part of the Phase 3 segment of INOVIO's global Phase 2/3 trial, INNOVATE ( IN OVIO I NO -4800 Va ccine T rial for E fficacy), for its DNA vaccine candidate for COVID-19, INO-4800.

INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico

Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit Conference (Transcript)

Dynavax Technologies

GlaxoSmithKline

Novavax

Sanofi

Their vaccines could be late to the party. But the stocks might still be big winners.

5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch

Amarin Corporation Plc

Intercept Pharma

Plug Power

Zogenix

If these high-water price targets come to fruition, investors will be all smiles.

5 Stocks With 195% to 467% Upside, According to Wall Street

PLYMOUTH MEETING, Pa. , Sept. 1, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that Dr. J.

INOVIO to Present at Upcoming Investor Conferences in September

The stock price of INOVIO (NASDAQ: INO) increased by 3.08% today. This is why it happened.

INO Stock: 3.08% Increase Explanation

The vaccine maker received some good news from Brazil.

Why Inovio Stock Is Jumping Today

Inovio Pharmaceuticals Inc. (NASDAQ:INO) shares are trading higher Thursday after the company announced it received regulatory authorization from Brazil's ANVISA to initiate the global Phase 3 segment of its Phase 2/3 trial for INO-4800. Inovio Pharmaceuticals stock was up 9.3% at $9.22 at last check.

Inovio Pharmaceuticals Stock Nears End Of Technical Pattern

The regulatory authority of Brazil has signed off Inovio Pharmaceuticals Inc's (NASDAQ: INO) global Phase 3 segment of its INNOVATE Phase 2/3 trial for INO-4800, DNA COVID-19 vaccine candidate. Related Content:   Inovio's DNA COVID-19 Vaccine Candidate Triggers Immune Response In Pivotal Study.

Inovio To Start Global Late-Stage COVID-19 Vaccine Trial

PLYMOUTH MEETING, Pa., Aug. 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has received regulatory authorization from Brazil's ANVISA (Agência Nacional de Vigilância Sanitária), the national health regulatory agency of Brazil, to initiate the global Phase 3 segment of its Phase 2/3 trial, INNOVATE ( IN OVIO I NO -4800 Va ccine T rial for E fficacy), for INO-4800, its DNA vaccine candidate for COVID-19.

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800

Baidu

New Oriental Education & Technology Group

GameStop

These widely held stocks were on successful money managers' chopping blocks in Q2.

5 Popular Stocks Billionaires Couldn't Sell Fast Enough in the Second Quarter

Investors appeared to be rattled by the U.S. government's decision to move forward with booster doses of mRNA vaccines.

Why Dynavax, Novavax, and Inovio Stocks Sank This Week

Planet Fitness

Our Fool roundtable picks three COVID stocks they think are dangerous at these prices.

3 Scary COVID Stocks to Avoid

Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares are trading higher Thursday alongside other vaccine maker stocks. Stocks have been trading higher recently as the COVIS-19 delta variant has been spreading throughout the U.S. Inovio Pharmaceuticals was up 13.45% at $9.70 at last check Thursday.

Watch Out: Inovio Pharmaceuticals Is Heating Up

GT Biopharma Inc

iShares Nasdaq Biotechnology ETF

Health Care Select Sector SPDR Fund

Merck's FDA and coronavirus vaccine news sparked momentum in biotech stocks today. Here are 4 to watch.

Former Penny Stocks To Watch After Merck's (MRK) Latest FDA Win

Solid business developments did not please investors.

Why Inovio Pharmaceuticals Is Plunging Today

Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Q2 2021 Results - Earnings Call Transcript

Inovio (INO) delivered earnings and revenue surprises of -56.00% and -1.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Inovio Pharmaceuticals (INO) Reports Q2 Loss, Misses Revenue Estimates

Shares of Inovio Pharmaceuticals (NASDAQ:INO) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 95.00% year over year to ($0.39), which missed the estimate of ($0.25).

Recap: Inovio Pharmaceuticals Q2 Earnings

PLYMOUTH MEETING, Pa., Aug. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended June 30, 2021.

INOVIO Reports Second Quarter 2021 Financial Results

PLYMOUTH MEETING, Pa. and SUZHOU, China, Aug. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has received regulatory allowance for two clinical trials investigating heterologous boosting with INO-4800, its DNA vaccine candidate for COVID-19, through partner and trial-sponsor Advaccine Biopharmaceuticals Suzhou Co., Ltd.

INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate

Its vaccine candidate might be too far behind to matter.

What Does the Delta Variant Mean for Inovio Pharmaceuticals' Stock?

PLYMOUTH MEETING, Pa., Aug. 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that the company has dosed the first Phase 2 trial subject in its quest to develop the first vaccine against the Middle East Respiratory Syndrome (MERS).

INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease

Annovis Bio

Are penny stocks worth it? Take a look at these 3 seeing explosive moves this year.

News for Inovio Pharmaceuticals Stock (INO)